

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (ef-53) TELISOTUZUMAB VEDOTIN

PRONUNCIATION tel eye" soe tooz' ue mab ve doe' tin

THERAPEUTIC CLAIM Treatment of cancer

CHEMICAL NAMES

1. Immunoglobulin G1, anti-(human hepatocyte growth factor receptor) (human-*Mus musculus* monoclonal ABT-700 heavy chain), disulfide with human-*Mus musculus* monoclonal ABT-700 κ-chain, dimer, thioether with *N*-[[[4-[[*N*-[6-(3-mercapto-2,5-dioxo-1-pyrrolidinyl)-1-oxohexyl]-*L*-valyl-*N*⁵-(aminocarbonyl)-*L*-ornithyl]amino]phenyl]methoxy]carbonyl]-*N*-methyl-*L*-valyl-*N*-[(1*S*,2*R*)-4-[(2*S*)-2-[(1*R*,2*R*)-3-[[1*R*,2*S*)-2-hydroxy-1-methyl-2-phenylethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]-1-pyrrolidinyl]-2-methoxy-1-[(1*S*)-1-methylpropyl]-4-oxobutyl]-*N*-methyl-*L*-valinamide
2. Immunoglobulin G1-kappa, anti-(human hepatocyte growth factor receptor (HGF receptor, proto-oncogene c-Met, scatter factor receptor, tyrosine-protein kinase Met, EC=2.7.10.1)); humanized mouse monoclonal antibody; γ1 heavy chain (1-445) [humanized VH (*Homo sapiens* IGHV1-2*02 (93%) –(IGHD)-IGHJ4*01) [8.8.11] (1-118) -*Homo sapiens* IGHG1*03{H K⁷>C(222),T⁸>-(del),T¹⁰>-(del), CH3 K107>-(del)} (119-445)] (221-218')-disulfide with kappa light chain (1'-218') [humanized V-KAPPA (*Homo sapiens* IGKV4-1*01 (85%) –IGKJ4*01) [10.3.9] (1'-111') -*Homo sapiens* IGKC*01 (112'-118')], dimer (223-223":225-225":228-228")-trisdisulfide, some of the interchain disulfide bridges are reduced and an average of 3 cysteines are *S*-substituted by (3*RS*)-1-[(8*S*,11*S*)-11-[(4-[(5*S*,8*S*,11*S*,12*R*)-14-[(2*S*)-2-[(1*R*,2*R*)-3-[(1*R*,2*S*)-2-hydroxy-1-methyl-2-phenylethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-12-methoxy-4,10-dimethyl-5,8-bis(1-methylethyl)-11-[(1*S*)-1-methylpropyl]-3,6,9,14-tetraoxo-2-oxa-4,7,10-triazatetradecyl]phenyl)acetyl]-8-(1-methylethyl)-6,9,16-trioxo-7,10,15,17-tetraazaheptadecyl]-2,5-dioxo-1*H*-pyrrolidin-3-yl radicals

STRUCTURAL FORMULA

Heavy chain

| | | | | | |
|-------------------------|------------|------------|------------|------------|-----|
| QVQLVQSGAE | VKKPGASVKV | SCKASGYIFT | AYTMHWVRQA | PGQGLEWMGW | 50 |
| IKPNNGLANY | AQKFQGRVTM | TRDTSISTAY | MELSLRSDD | TAVYYCARSE | 100 |
| ITTEFDYWGQ | GTLVTVSSAS | TKGPSVFPLA | PSSKSTSGGT | AALGCLVKDY | 150 |
| FPEPVTVSWN | SGALTSGVHT | FPAVLQSSGL | YSLSSVVTVP | SSSLGTQTYI | 200 |
| CNVN ⁴ KPSNT | KVDKRVEPKS | CDCHCPPCPA | PELLGGPSVF | LFPKPKDTL | 250 |
| MISRTPEVTC | VVDVSHEDP | EVKFNWYVDG | VEVHNAKTKP | REEQYNSTYR | 300 |
| VVSVLTIVLHQ | DWLNGKEYKC | KVSNKALPAP | IEKTISKAKG | QPREPQVYTL | 350 |
| PPSREEMTKN | QVSLTCLVKG | FYPSDIAVEW | ESNGQPENNY | KTTPPVLDSD | 400 |
| GSFFLYSKLT | VDKSRWQQGN | VFSCSVMHEA | LHNHYTQKSL | SLSPG | 445 |

Light chain

| | | | | | |
|------------|------------|------------|------------|------------|------|
| DIVMTQSPDS | LAVSLGERAT | INCKSSESVD | SYANSFLHWY | QQKPGQPPKL | 50' |
| LIYRASTRES | GVPDRFSGSG | SGTDFTLTIS | SLQAEDVAVY | YCQQSKEDPL | 100' |

TELISOTUZUMAB VEDOTIN

April 26, 2017


| | | | | | |
|------------|------------|------------|-----------|------------|------|
| TFGGGTKVEI | KRTVAAPSVF | IFPPSDEQLK | SGTASVCLL | NNFYPREAKV | 150' |
| QWKVDNALQS | GNSQESVTEQ | DSKDSTYSLS | STLTLKADY | EKHKVYACEV | 200' |
| THQLSSPVT | KSFNRGEC | | | | 218' |

Disulfide bridges

| | | | | | |
|-----------|------------|-----------|--------------|-----------|-------------|
| 22-96 | 22"-96" | 23'-92' | 23""-92"" | 138'-198' | 138""-198"" |
| 145-201 | 145""-201" | 218'-221* | 218""-221""* | 223-223"* | 225-225""* |
| 228-228"* | 260-320 | 260"-320" | 366-424 | 366"-424" | |

* partly reduced and *S*-substituted with vedotin.

Modified residues



Glycosylation sites (N)

Asn-296 Asn-296"

MOLECULAR FORMULA $C_{6440}H_{9978}N_{1724}O_{2022}S_{50}$

MOLECULAR WEIGHT 145.5 kDa

TRADEMARK None as yet

SPONSOR AbbVie

CODE DESIGNATIONS ABBV-399

CAS REGISTRY NUMBER 1714088-51-3

UNII 976X9VXC3Z

WHO NUMBER 10365

gbk